Brian Pittman
Statistician 3Cards
About
Research
Publications
2026
Effects of Age and BMI on Histamine H3 Receptor Availability in Healthy Humans (P3-12.005)
Yang Y, Ibrahim W, Gravel P, pittman B, Hoye J, Sadabad F, Cool R, Zheng M, Pittenger C, Gallezot J, Carson R, Huang H, Radhakrishnan R, Matuskey D. Effects of Age and BMI on Histamine H3 Receptor Availability in Healthy Humans (P3-12.005). Neurology 2026, 106 DOI: 10.1212/wnl.0000000000212778.Peer-Reviewed Original ResearchReversible alterations of brain acetate metabolism associated with alcohol consumption
Kumaragamage C, Jiang L, Angarita G, de Graaf R, Guidone E, Coppoli A, Behar K, Gulanski B, Pittman B, Weinzimer S, Rothman D, Krystal J, Mason G. Reversible alterations of brain acetate metabolism associated with alcohol consumption. Neuropsychopharmacology 2026, 1-9. PMID: 42218273, DOI: 10.1038/s41386-026-02455-6.Peer-Reviewed Original ResearchAlcohol use disorderAlcohol use disorder patientsGlutamate-glutamine neurotransmitter cyclingMedically supervised detoxificationsHeavy drinkersAlcohol consumptionWithin-subject comparisonsLD participantsWeeks abstinenceBrain glucose uptakeUse disorderTreatment-seekingLight drinkersGlutamate-glutamineMagnetic resonance spectroscopyMonths to levelsGlutamate-glutamine cycleNeurotransmitter cyclingGroup effectCerebral metabolic rateDrinkersAbstinenceLong-term recoveryBrainParticipantsAn opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol
P. A. Costa G, Sofuoglu M, Compton P, Ranganathan M, Pittman B, De Aquino J. An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol. Neuropsychopharmacology 2026, 1-10. PMID: 42162267, PMCID: PMC13213852, DOI: 10.1038/s41386-026-02443-w.Peer-Reviewed Original ResearchOpioid use disorderOpioid agonist treatmentChronic painPain modulationDose-dependent effectAgonist treatmentTemporal summationTemporal summation of painPlacebo-controlled crossover studyUse disorderSignificant linear dose responseHuman laboratory paradigmsNon-opioid adjunctsConditioned pain modulationEndogenous pain modulationDescending pain inhibitionHeat pain thresholdQuantitative sensory testingEffects of cannabidiolCue-induced cravingAssociated with significant reductionsCognitive performanceOral cannabidiolPain inhibitionDouble-blind444. Social-Emotional Regulation During a Naturalistic fMRI Task in Non-Autistic and Autistic Adults
Hyatt C, Diefenbach G, Mazefsky C, Dichter G, Wexler B, Pittman B, Pearlson G, Assaf M. 444. Social-Emotional Regulation During a Naturalistic fMRI Task in Non-Autistic and Autistic Adults. Biological Psychiatry 2026, 99: s290. DOI: 10.1016/j.biopsych.2026.03.678.Peer-Reviewed Original Research673. Sex-Specific Associations Between White Matter Tract Integrity and Alcohol Consumption in UK Biobank Participants
Mayberry H, Zhou H, Pittman B, McKee S, Cosgrove K, Zakiniaeiz Y. 673. Sex-Specific Associations Between White Matter Tract Integrity and Alcohol Consumption in UK Biobank Participants. Biological Psychiatry 2026, 99: s388. DOI: 10.1016/j.biopsych.2026.03.907.Peer-Reviewed Original ResearchLower synaptic density in mood circuitry underlies depression in Parkinson’s disease
Cayir S, Naganawa M, Volpi T, Sadabad F, Dias M, Yang Y, Elliott S, Ansari M, Elshahat A, Pittman B, Esterlis I, Nabulsi N, Huang Y, Sanacora G, Comley R, Finnema S, Carson R, Tinaz S, Matuskey D, Holmes S. Lower synaptic density in mood circuitry underlies depression in Parkinson’s disease. Brain Communications 2026, 8: fcag136. PMID: 42109687, PMCID: PMC13152014, DOI: 10.1093/braincomms/fcag136.Peer-Reviewed Original ResearchAnterior cingulate cortexDepressive symptomsSynaptic densityMood-related brain regionsSeverity of depressive symptomsParkinson's diseaseDorsolateral prefrontal cortexSymptoms of depressionPrefrontal cortexCingulate cortexComorbid depressionBrain regionsBinding potentialParkinson's disease patientsDepressionSynaptic plasticitySynaptic vesicle protein 2AMoodMotor symptomsDLPFCAmygdalaHealthy controlsHippocampusEvaluation of interventionsCortexSynaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 18F‐SynVesT‐1 and 18F‐FDG PET
Fesharaki‐Zadeh A, Cayir S, Ibrahim W, Yang Y, Gallezot J, Naganawa M, Wu Y, Toyonaga T, Sadabad F, O'Dell R, Pittman B, Nabulsi N, Strittmatter S, Carson R, Huang Y, van Dyck C, Mecca A, Matuskey D. Synaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 18F‐SynVesT‐1 and 18F‐FDG PET. Alzheimer's & Dementia 2026, 22: e71283. PMID: 41954197, PMCID: PMC13063251, DOI: 10.1002/alz.71283.Peer-Reviewed Original ResearchThis study investigates synaptic density imaging in behavioral variant frontotemporal dementia, showing that SV2A PET detects more pronounced synaptic loss than glucose hypometabolism using FDG PET, aiding early diagnosis and monitoring.Additional analyses do not implicate opioid signaling in the antidepressant effects of ketamine
Yoon G, Pittman B, Krystal J. Additional analyses do not implicate opioid signaling in the antidepressant effects of ketamine. The International Journal Of Neuropsychopharmacology 2026, 29: pyag011. PMID: 41818343, PMCID: PMC13064640, DOI: 10.1093/ijnp/pyag011.Peer-Reviewed Original ResearchNaltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms
McKee S, Lydecker J, Pittman B, Jastreboff A, DiLeone R, Lavery M, Grilo C. Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms. Drug And Alcohol Dependence Reports 2026, 19: 100428. PMID: 41867954, PMCID: PMC13000475, DOI: 10.1016/j.dadr.2026.100428.Peer-Reviewed Original ResearchHuman laboratory studiesBinge-eating disorderRandomized clinical trialsBrain reward systemHunger ratingsHigh-caloric foodPlasma levelsPsychosocial impairmentEating episodesFood cravingsReward systemCravingEating behaviorsEarly treatment responseNaltrexone/bupropionPotential markersTreatment responseSweet snacksClinical trialsDisordersSecondary outcomesEffective treatmentInvestigation of mechanismsEffective therapeuticsSnack foodsLegal blood alcohol concentration limits and alcohol-attributable traffic mortality rates: an analysis across 165 countries
Jimenez Chavez C, Peltier M, Mokwuah A, Bin-Mahfouz A, Verplaetse T, Zakiniaeiz Y, Kohler R, Garcia-Rivas V, Banini B, Raval N, Pittman B, McKee S. Legal blood alcohol concentration limits and alcohol-attributable traffic mortality rates: an analysis across 165 countries. EClinicalMedicine 2026, 93: 103794. PMID: 41768275, PMCID: PMC12945517, DOI: 10.1016/j.eclinm.2026.103794.Peer-Reviewed Original ResearchGender inequalityTraffic mortality ratesNational incomeWorld Health OrganizationAge-standardized death ratesAlcohol consumptionPer capita alcohol consumptionCountry-level indicatorsHigh alcohol consumptionHealthcare system infrastructureAssistant SecretaryMortality rateStructural factorsAlcohol-impaired drivingRoad traffic deathsMortality burdenPopulation riskGlobal burdenMultilevel analysisStructural conditionsPrimary outcomeBlood alcohol concentration limitBlood alcohol concentrationDeath rateHealth Organization
News
News
- July 01, 2026
Bassir Nia, Co-Investigators to Study Cannabinoid Receptor Type 1 Availability in Individuals with Opioid Use Disorder
- May 21, 2026Source: Neuropsychopharmacology
An Opioid-Withholding Human Laboratory Paradigm During Opioid Agonist Treatment for Opioid Use Disorder and Chronic Pain: Phase- and Dose-Dependent Effects of Cannabidiol
- January 20, 2026
Yale Study: Higher Drinking Frequency Corresponds to Lower Synaptic Density in People with Alcohol Use Disorder
- July 29, 2025Source: Journal of Addiction Medicine
The Role of Childhood Trauma in Chronic Pain and Substance Use Among Individuals Receiving Methadone Treatment for Opioid Use Disorder